These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 11739991)

  • 1. Joint effect of the APOE gene and midlife systolic blood pressure on late-life cognitive impairment: the Honolulu-Asia aging study.
    Peila R; White LR; Petrovich H; Masaki K; Ross GW; Havlik RJ; Launer LJ
    Stroke; 2001 Dec; 32(12):2882-9. PubMed ID: 11739991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study.
    Launer LJ; Masaki K; Petrovitch H; Foley D; Havlik RJ
    JAMA; 1995 Dec; 274(23):1846-51. PubMed ID: 7500533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Midlife blood pressure and dementia: the Honolulu-Asia aging study.
    Launer LJ; Ross GW; Petrovitch H; Masaki K; Foley D; White LR; Havlik RJ
    Neurobiol Aging; 2000; 21(1):49-55. PubMed ID: 10794848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lowering midlife levels of systolic blood pressure as a public health strategy to reduce late-life dementia: perspective from the Honolulu Heart Program/Honolulu Asia Aging Study.
    Launer LJ; Hughes T; Yu B; Masaki K; Petrovitch H; Ross GW; White LR
    Hypertension; 2010 Jun; 55(6):1352-9. PubMed ID: 20404223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired olfaction as a marker for cognitive decline: interaction with apolipoprotein E epsilon4 status.
    Graves AB; Bowen JD; Rajaram L; McCormick WC; McCurry SM; Schellenberg GD; Larson EB
    Neurology; 1999 Oct; 53(7):1480-7. PubMed ID: 10534255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of APOE-epsilon4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging.
    Bretsky P; Guralnik JM; Launer L; Albert M; Seeman TE;
    Neurology; 2003 Apr; 60(7):1077-81. PubMed ID: 12682309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease.
    Kivipelto M; Helkala EL; Laakso MP; Hänninen T; Hallikainen M; Alhainen K; Iivonen S; Mannermaa A; Tuomilehto J; Nissinen A; Soininen H
    Ann Intern Med; 2002 Aug; 137(3):149-55. PubMed ID: 12160362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive medication use and risk of cognitive impairment: the Honolulu-Asia Aging Study.
    Gelber RP; Ross GW; Petrovitch H; Masaki KH; Launer LJ; White LR
    Neurology; 2013 Sep; 81(10):888-95. PubMed ID: 23911753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Midlife pulse pressure and incidence of dementia: the Honolulu-Asia Aging Study.
    Freitag MH; Peila R; Masaki K; Petrovitch H; Ross GW; White LR; Launer LJ
    Stroke; 2006 Jan; 37(1):33-7. PubMed ID: 16339468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrovascular disease, APOE epsilon4 allele and cognitive decline in a cognitively normal population.
    Qiu C; Winblad B; Fratiglioni L
    Neurol Res; 2006 Sep; 28(6):650-6. PubMed ID: 16945218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons.
    Haan MN; Shemanski L; Jagust WJ; Manolio TA; Kuller L
    JAMA; 1999 Jul; 282(1):40-6. PubMed ID: 10404910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood pressure interacts with APOE ε4 to predict memory performance in a midlife sample.
    Oberlin LE; Manuck SB; Gianaros PJ; Ferrell RE; Muldoon MF; Jennings JR; Flory JD; Erickson KI
    Neuropsychology; 2015 Sep; 29(5):693-702. PubMed ID: 25730733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihypertensive medication is associated with less cognitive impairment in the very old with apolipoprotein-E epsilon4 allele.
    Hestad KA; Engedal K
    Drugs Aging; 2006; 23(9):723-31. PubMed ID: 17020396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of midlife blood pressure to late-life cognitive decline and brain morphology.
    Swan GE; DeCarli C; Miller BL; Reed T; Wolf PA; Jack LM; Carmelli D
    Neurology; 1998 Oct; 51(4):986-93. PubMed ID: 9781518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood pressure and risk of incident Alzheimer's disease dementia by antihypertensive medications and APOE ε4 allele.
    Rajan KB; Barnes LL; Wilson RS; Weuve J; McAninch EA; Evans DA
    Ann Neurol; 2018 May; 83(5):935-944. PubMed ID: 29637601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APOE epsilon4 and cognitive decline in older stroke patients with early cognitive impairment.
    Ballard CG; Morris CM; Rao H; O'Brien JT; Barber R; Stephens S; Rowan E; Gibson A; Kalaria RN; Kenny RA
    Neurology; 2004 Oct; 63(8):1399-402. PubMed ID: 15505155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging.
    Hsiung GY; Sadovnick AD; Feldman H
    CMAJ; 2004 Oct; 171(8):863-7. PubMed ID: 15477624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The joint effect of apolipoprotein E epsilon4 and MRI findings on lower-extremity function and decline in cognitive function.
    Carmelli D; DeCarli C; Swan GE; Kelly-Hayes M; Wolf PA; Reed T; Guralnik JM
    J Gerontol A Biol Sci Med Sci; 2000 Feb; 55(2):M103-9. PubMed ID: 10737693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APOE genotype modifies the relationship between midlife vascular risk factors and later cognitive decline.
    Bangen KJ; Beiser A; Delano-Wood L; Nation DA; Lamar M; Libon DJ; Bondi MW; Seshadri S; Wolf PA; Au R
    J Stroke Cerebrovasc Dis; 2013 Nov; 22(8):1361-9. PubMed ID: 23601373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and risk factors for mild cognitive impairment: a population-based three-year follow-up study of cognitively healthy elderly subjects.
    Tervo S; Kivipelto M; Hänninen T; Vanhanen M; Hallikainen M; Mannermaa A; Soininen H
    Dement Geriatr Cogn Disord; 2004; 17(3):196-203. PubMed ID: 14739544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.